RxDoctor Payments Data

Glen Stone

Optometrist · Batesville, MSNPI 1992817597

Payments from drug & device makers

$2,673in general payments, 2019–2025

Across 64 payments — averaging $41.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$683
  • Alcon$571
  • Optos, Inc.$413
  • Coopervision Inc.$171
  • Bausch & Lomb Americas Inc.$160
  • Eyevance Pharmaceuticals LLC$125
  • plus $548 from 8 others

What the payments were for

  • Food & beverage$2,27385%
  • Entertainment$40015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,673 in reported general payments places this provider in the 80th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$136,063
Medicare patients
596
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost138$66,060
RestasisCyclosporine46$35,337
Alphagan PBrimonidine Tartrate31$12,963
VyzultaLatanoprostene Bunod23$10,942
CombiganBrimonidine Tartrate/Timolol23$9,785
Latanoprost809$5,989
Travoprost30$3,516
Brimonidine Tartrate126$3,249
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,529
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat178$2,504
Dorzolamide Hcl61$1,299
Tobramycin-DexamethasoneTobramycin/Dexamethasone31$1,260
Prednisolone Acetate24$1,051
Timolol Maleate85$657
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha41$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$683$124,144238 claims
Bausch & Lomb Americas Inc.Vyzulta$160$10,94223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Batesville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →